Reducing Discontinuities in Pharmaceutical Scale-Up

Overview

Successful pharmaceutical scale-up depends on more than increased production capacity. Continuity across processing parameters or the geometry of equipment is essential. Scale-up challenges often arise when multiple geometric and operational changes are introduced simultaneously, making it difficult to identify the sources of variability. If the material’s processing environment changes, outcomes may be different than what is desired, even when operating conditions appear proportionally scaled. Predictable scale-up is achieved by deliberately preserving key process drivers, introducing changes incrementally, and aligning critical parameters across different scales. By minimizing discontinuities, manufacturers can improve process predictability and ensure consistent product performance from development through commercial production.

Why continuity across equipment, parameters, and unit operations determines success

Scale-up rarely fails because a process is fundamentally unsound. More often, challenges arise when modifications are introduced to the pharmaceutical production process without fully accounting for those changes’ consequences. When using twin-screw extruders  in pharmaceutical manufacturing, the equipment size may be increased, or the feeding configuration may change, or downstream handling may be adjusted. While each of these transitions could be reasonable on its own, when implemented together their cumulative impact can make the root-cause identification of scale-up failures significantly more complex.

The issue is not scaling itself. It is the discontinuities introduced during scaling.

As development progresses from laboratory to pilot scale and eventually to production, transitions are inevitable: Throughput increases; equipment geometry changes; unit operations evolve. Each transition alters the physical or operational environment in which the material is processed. Predictable scale-up depends on managing each modification deliberately.

Physical discontinuities: When size alters behavior

One of the most common discontinuities arises when moving between extruder sizes. Understanding this is not meant to discourage scaling, but to clarify where careful attention is required.

As screw diameter increases, surface area increases with the square of the diameter, while material volume increases with the cube. Thus the ratio between thermal exchange surface and material mass shifts too. In larger systems, less surface area is available per unit volume to introduce or remove heat.

A useful way to consider how this affects scale-up is to imagine two systems operating at proportionally similar setpoints. On paper, screw speed and feed rate may appear correctly scaled. Yet inside the barrel, the larger system retains heat differently and distributes mechanical energy differently. From the material’s perspective, the environment is not identical, even if the numerical settings are.

In controlled scale-up investigations across geometrically similar 11 mm, 16 mm, and 24 mm twin-screw extruders, it has been shown that maintaining comparable mean residence time and specific mechanical energy consumption results in closely aligned process behavior across scales. However, these parameters do not remain constant automatically when diameter changes. They must be adjusted intentionally.

If feed rate is increased according to geometric scaling alone, residence time distribution may shift. If screw speed is not modified appropriately, specific mechanical energy may change, influencing melt temperature and mixing intensity.

In practice, these differences rarely present as immediate failures. Instead, a process that once operated comfortably within its design window may begin to require tighter control. Dissolution may remain within specification, but variability increases. Operators may find that small parameter adjustments produce larger effects than before.

When the extruder size changes, surface area and volume change at different rates, and the physical relationships governing the process change too. The practical response is not to avoid scaling, but to identify which parameters must be preserved to recreate the same material experience.

Process discontinuities: When workflow changes accumulate

Not all discontinuities are geometric. Many are operational.

Here are just a few examples of minor operational changes that could have an outsized effect:

  • A laboratory process may use hand-cut strands before milling, while production employs pelletization or chill-roll flaking.
  • A small gravimetric feeder may be replaced with a higher-capacity system.
  • Degassing configuration may be altered, or screw elements may be rearranged to accommodate higher throughput.

When multiple transitions occur simultaneously, diagnosing the source of variability becomes more difficult. Was it the larger diameter? The modified pelletizer? The adjusted screw configuration? The higher feed rate?

Each modification may seem minor when evaluated independently. Yet from the material’s perspective, the sequence of thermal and mechanical exposures has changed.

Research on downstream processing of hot-melt extruded amorphous dispersions has demonstrated how upstream conditions influence milling efficiency, particle size distribution, tablet tensile strength, and dissolution behavior. A modest shift in residence time or energy input during extrusion can propagate through the workflow, but not really become visible until later during compression testing.
 
The solution is not to eliminate changes, but to structure them properly. Introducing adjustments incrementally and limiting the number of simultaneous modifications reduces uncertainty and simplifies interpretation.

Designing continuity into the scale-up strategy

Continuity does not mean resisting growth in capacity. It means planning scale transitions so that the dominant physical drivers remain aligned.

Several practical steps support this approach:

  • Maintain geometrically similar screw and barrel ratios across scales whenever possible.
  • Match specific mechanical energy consumption and mean residence time rather than relying solely on proportional feed-rate scaling.
  • Adjust screw speed deliberately to compensate for thermal exchange differences introduced by larger diameters.
  • Define process boundaries at development scale using design-of-experiments approaches before transferring to larger systems.
  • Introduce equipment or workflow changes in stages rather than simultaneously whenever feasible.

In structured scale-up studies of hot-melt extrusion processes, overlapping design spaces based on residence time, melt temperature, and specific mechanical energy have enabled more predictable transfer between extruder sizes. In some cases, this understanding has supported one-step scale-up procedures with minimal re-optimization.

These outcomes are not accidental. They reflect disciplined management of change.

What controlled continuity means in practice

From an operational standpoint, reducing discontinuities requires focused questioning:

  • Are we modifying equipment size and downstream handling at the same time?
  • Have we measured residence time distribution at both scales rather than assuming similarity?
  • Is specific mechanical energy being monitored and aligned across systems?
  • Are we relying primarily on barrel heating, or allowing screw work to provide controlled energy input?

Scale-related variability rarely originates from a single dramatic deviation. It more often emerges from several modest shifts introduced simultaneously. Separating those shifts and managing them individually makes deviations easier to detect and correct.

In other words: Limit the number of uncontrolled changes at each transition.

Conclusion

Continuity as a scaling principle

Across development and production environments, successful pharmaceutical scale-up using twin-screw extrusion reflects a consistent approach: Understand what governs material transformation, and preserve that continuity as conditions change.

Discontinuities—whether geometric or operational—introduce uncertainty. Continuity reduces it.

Scale is not defined solely by equipment size. It is defined by the ability to extend a process into a new operational context without altering the physical drivers that determine product performance.

When transitions are structured around preserving material experience, scaling becomes an extension of process knowledge rather than a reinvention of it. Predictable scale-up, in practice, is achieved not by avoiding change, but by managing it deliberately.

  • There are several critical process paraments (CPPs) that affect extrusion and the scale-up process:
    • Barrel temperature profile
    • Screw speed
    • Feed rate
    • Specific mechanical energy (SME)
    • Residence time
    • Torque
    • Die pressure

  • During the extrusion process, it is critical to control feed rates as materials are introduced into the system; process parameters like temperature, specific mechanical energy (SME), shear, and torque; and residence time distribution. The screw design and control of the continuous feeders are also very important to the production of consistent, repeatable pharmaceutical products.

  • Examples of pharmaceutical produced via extrusion include amorphous solid dispersions (ASDs), hot-melt extruded tablets, oral solid dosage (OSD) forms, and granules for tablet compression. Extrusion can also be used to make drug-loaded implants and transdermal systems, such as biodegradable implants that can be injected into a patient’s subcutaneous tissue.

  • Common PAT tools can be integrated with a twin-screw extruder to monitor the products as they are formed. Some of these, like NIR spectroscopy and Raman spectroscopy, can be employed in real time to generate feedback that permits immediate adjustments of the process parameters. Other technologies include rheometers, melt pressure sensors, or more traditional temperature controls.

  • Scale-up is the use of larger equipment or reactions vessels to increase the capacity of production, while scale-out is the replication of existing equipment to achieve greater outputs. For scale-out, instead of using massive, hard-to-scale mixing machines, pharmaceutical companies often replicate identical, smaller automated processing units to increase capacity safely and incrementally. With twin-screw extrusion, various sizes of extruders are available that make scale-up possible while maintaining continuity and control.

Dirk Leister

Written by:

Dirk Leister

Manager Applications & Customer Support , Thermo Fisher Scientific

Dirk Leister is a marketing manager at Thermo Fisher Scientific focused on extruder and compounder technology used in the pharmaceutical, food, and polymer industries.

Read more Leister, Dirk

Leave a Reply

Your email address will not be published. Required fields are marked *